Weight Gain, Metabolic Disturbances, and Physical Health Care in a Brazilian Sample of Outpatients with Schizophrenia

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2013 Jan 29

PMID 23355783

Citations 5

Authors

Pedro Caldana Gordon

Josefa Cynara Xavier

Mario Rodrigues Louza

Affiliations

Soon will be listed here.

Abstract

Background: In the last few decades, a large number of studies have produced compelling evidence that patients with schizophrenia are at increased risk for developing several medical conditions and diseases, including obesity, metabolic disturbances, and cardiovascular diseases. Several protocols have been designed with the aim of reducing such risk.

Objective: To investigate current physical health status in a population of outpatients with schizophrenia.

Methods: A cross-sectional study was conducted in our outpatient clinic, selecting subjects who met DSM-IV diagnosis criteria for schizophrenia. Data were collected regarding clinical characteristics, lifestyle, medication in use, and biometric and laboratory parameters.

Results: A total of 261 patients were included. We found a high prevalence of elevated body mass index (BMI . 25) (70%), dyslipidemia (73.2%), and metabolic syndrome (28.7%). Patients' ages were associated with worsened lipid profiles, but other variables, such as disorder duration or type of antipsychotic in use, were not associated with any metabolic disturbance. Despite the increased prevalence of these conditions, only a small portion of the sample was under regular medical treatment.

Conclusion: Outpatients with schizophrenia show signs of poor physical health conditions. These findings reinforce the need for an intensive and appropriate approach to assure that these patients receive adequate clinical referral and treatment.

Citing Articles

Turkish Adaptation of the Health Improvement Profile for the Evaluation of Physical Well-Being of Individuals With Severe Mental Illness.

Murat M, Kutlu F Florence Nightingale J Nurs. 2024; 32(2):168-183.

PMID: 39552166 PMC: 11332440. DOI: 10.5152/FNJN.2024.23085.

The psychosis metabolic risk calculator (PsyMetRiC) for young people with psychosis: International external validation and site-specific recalibration in two independent European samples.

Perry B, Vandenberghe F, Garrido-Torres N, Osimo E, Piras M, Vazquez-Bourgon J Lancet Reg Health Eur. 2022; 22:100493.

PMID: 36039146 PMC: 9418905. DOI: 10.1016/j.lanepe.2022.100493.

Non-psychiatric hospitalization length-of-stay for patients with psychotic disorders: A mixed methods study.

Weissinger G, Brooks Carthon J, Brawner B Gen Hosp Psychiatry. 2020; 67:1-9.

PMID: 32866772 PMC: 7722147. DOI: 10.1016/j.genhosppsych.2020.07.007.

An Integrative Program to Reduce Stigma in Primary Healthcare Workers Toward People With Diagnosis of Severe Mental Disorders: A Protocol for a Randomized Controlled Trial.

Grandon P, Saldivia S, Vaccari P, Ramirez-Vielma R, Victoriano V, Zambrano C Front Psychiatry. 2019; 10:110.

PMID: 30899230 PMC: 6416206. DOI: 10.3389/fpsyt.2019.00110.

Metabolic syndrome in schizophrenia.

Malhotra N, Grover S, Chakrabarti S, Kulhara P Indian J Psychol Med. 2013; 35(3):227-40.

PMID: 24249923 PMC: 3821198. DOI: 10.4103/0253-7176.119471.

References

Saha S, Chant D, McGrath J . A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007; 64(10):1123-31. DOI: 10.1001/archpsyc.64.10.1123. View

Daumit G, Goff D, Meyer J, Davis V, Nasrallah H, McEvoy J . Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res. 2008; 105(1-3):175-87. PMC: 2614656. DOI: 10.1016/j.schres.2008.07.006. View

Hennekens C, Hennekens A, Hollar D, Casey D . Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005; 150(6):1115-21. DOI: 10.1016/j.ahj.2005.02.007. View

Majadas S, Olivares J, Galan J, Diez T . Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry. 2011; 53(2):145-51. DOI: 10.1016/j.comppsych.2011.03.009. View

Vancampfort D, Probst M, Knapen J, Carraro A, De Hert M . Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia. Psychiatry Res. 2012; 200(2-3):73-8. DOI: 10.1016/j.psychres.2012.03.046. View

Leitao-Azevedo C, Guimaraes L, Belmonte de Abreu M, Gama C, Lobato M, Belmonte-de-Abreu P . Increased dyslipidemia in schizophrenic outpatients using new generation antipsychotics. Braz J Psychiatry. 2007; 28(4):301-4. View

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

Millen B, Campbell G, Beasley C . Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials. J Psychopharmacol. 2010; 25(5):639-45. DOI: 10.1177/0269881110370505. View

Teixeira P, Rocha F . The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Braz J Psychiatry. 2008; 29(4):330-6. DOI: 10.1590/s1516-44462007000400007. View

10.

Smith M, Hopkins D, Peveler R, Holt R, Woodward M, Ismail K . First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2008; 192(6):406-11. DOI: 10.1192/bjp.bp.107.037184. View

11.

Ratliff J, Palmese L, Reutenauer E, Liskov E, Grilo C, Tek C . The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study. Compr Psychiatry. 2012; 53(7):1028-33. PMC: 3380150. DOI: 10.1016/j.comppsych.2012.02.003. View

12.

Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353(12):1209-23. DOI: 10.1056/NEJMoa051688. View

13.

Barnett A, Mackin P, Chaudhry I, Farooqi A, Gadsby R, Heald A . Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. J Psychopharmacol. 2007; 21(4):357-73. DOI: 10.1177/0269881107075509. View

14.

Misawa F, Shimizu K, Fujii Y, Miyata R, Koshiishi F, Kobayashi M . Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry. 2011; 11:118. PMC: 3155482. DOI: 10.1186/1471-244X-11-118. View

15.

De Hert M, Correll C, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I . Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011; 10(1):52-77. PMC: 3048500. DOI: 10.1002/j.2051-5545.2011.tb00014.x. View

16.

Tran E, Rouillon F, Loze J, Casadebaig F, Philippe A, Vitry F . Cancer mortality in patients with schizophrenia: an 11-year prospective cohort study. Cancer. 2009; 115(15):3555-62. DOI: 10.1002/cncr.24383. View

17.

Meyer J, Davis V, Goff D, McEvoy J, Nasrallah H, Davis S . Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res. 2008; 101(1-3):273-86. PMC: 3673564. DOI: 10.1016/j.schres.2007.12.487. View

18.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Asenjo Lobos C . Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010; 123(2-3):225-33. PMC: 2957510. DOI: 10.1016/j.schres.2010.07.012. View

19.

Leucht S, Corves C, Arbter D, Engel R, Li C, Davis J . Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2008; 373(9657):31-41. DOI: 10.1016/S0140-6736(08)61764-X. View

20.

Brown S . Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry. 1998; 171:502-8. DOI: 10.1192/bjp.171.6.502. View